CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 10 enrolled
Drug / intervention
biphasic insulin aspart 30 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01620424
NCT01620424Phase 1Completed
CompareCT.gov

A Randomised, Double-blind, Single-centre, Two-Period Crossover Trial Investigating the Pharmacokinetics and Pharmacodynamics of NN-X14Mix30 and NN-X14Mix50 in Type 2 Diabetic Patients

Novo Nordisk A/S·interventional·Posted Jun 15, 2012·Updated Jan 5, 2017

In Brief

A Phase 1 clinical trial evaluating biphasic insulin aspart 30 and biphasic insulin aspart 50 for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 10 participants across 1 site.

Detailed Summary

This trial is conducted in Japan. The aim of this trial is to investigate the pharmacokinetics and pharmacodynamics of biphasic insulin aspart 30 (NN-X14Mix30) and biphasic insulin aspart 50 (NN-X14Mix5050) in subjects with type 2 diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesJapan
Collaborators--

Timeline

Phase 1CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 15, 2012
Enrollment StartFeb 1, 2001
Primary CompletionApr 1, 2001
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 14.0 years ago

Interventions

biphasic insulin aspart 30drug

Single dose administered subcutaneously (s.c., under the skin) on two dosing vists. A wash-out period of 2-28 days will take place between dosing visits

biphasic insulin aspart 50drug

Single dose administered subcutaneously (s.c., under the skin) on two dosing vists. A wash-out period of 2-28 days will take place between dosing visits